Our study is the first evidence of a direct effect of CD162 in mediating resistance of AML cells to chemotherapy, and our in vitro data suggests that this effect may specifically involve the interaction of CD162 with E-selectin, not P-selectin. The gene discussed is SELPLG; the disease is acute myeloid leukemia.